Betty Chan, PhD

Principal Consultant

Betty brings nearly two decades of experience in drug discovery, with deep expertise in biochemistry, protein sciences, and lead discovery for small molecule therapeutics.

Throughout her career, she has built and scaled R&D capabilities at early-stage biotech companies, advancing programs from target validation through IND-enabling studies. At Auron Therapeutics, she established the protein sciences function and later expanded it to include cell-based assays and biomarker development. She also led discovery efforts for AUTX-703, a first-in-class KAT2A/B degrader now in Phase 1 clinical trials for relapsed/refractory AML and MDS.

Earlier in her career at H3 Biomedicine, Betty developed novel splicing assays and played a pivotal role in identifying and characterizing H3B-8800, a clinical-stage SF3B1 modulator. Her foundational work continued at X-Chem, Kymera Therapeutics, and Civetta Therapeutics, where she built core biochemical and biophysical capabilities and shaped hit-finding strategies across diverse target classes. Her work has resulted in 12 publications, 2 patents, and multiple presentations at conferences.

Betty holds a BS in Biology, Biochemistry, and French Language and Literature and a MS in Molecular and Cell Biology from Brandeis University. She earned her PhD in Biological Chemistry and Molecular Pharmacology from Harvard University.